In this context, we investigated the efficacy and safety of dalpiciclib in combination with an AI compared to NCT in patients with HR+ HER2 negative breast tumors, aiming to provide additional evidence to address the aforementioned questions. The gene discussed is ERBB2; the disease is breast neoplasm.